Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?

Because of the lack of a survival benefit, the suboptimal control arm design, and the overall health care costs, the authors do not believe that olaparib represents a major advance for patients with pancreatic cancer. The POLO trial illustrates that as a community, even in settings where there is a huge need, physicians must be rigorous in their methodology and mindful that they not lower the bar for new therapies. [ABSTRACT FROM AUTHOR]